Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash & Equivalents (2016 - 2025)

Angiodynamics (ANGO) has disclosed Cash & Equivalents for 16 consecutive years, with $41.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 23.02% year-over-year to $41.6 million, compared with a TTM value of $41.6 million through Nov 2025, down 23.02%, and an annual FY2025 reading of $55.9 million, down 26.51% over the prior year.
  • Cash & Equivalents was $41.6 million for Q4 2025 at Angiodynamics, up from $38.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $78.5 million in Q1 2024 and bottomed at $23.9 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $45.9 million, with a median of $44.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 56.14% in 2022, then skyrocketed 160.54% in 2024.
  • Year by year, Cash & Equivalents stood at $34.3 million in 2021, then dropped by 12.93% to $29.9 million in 2022, then surged by 103.96% to $60.9 million in 2023, then decreased by 11.18% to $54.1 million in 2024, then dropped by 23.02% to $41.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for ANGO at $41.6 million in Q4 2025, $38.8 million in Q3 2025, and $55.9 million in Q2 2025.